The document discusses various methods for predicting indolent or low-risk prostate cancer, including nomograms developed using retrospective data on tumor characteristics like PSA levels, Gleason scores, and biopsy results. Several nomograms are presented that provide probabilities of indolent disease or survival based on pre-treatment clinical factors. Compliance with treatment recommendations based on nomogram risk assessments is generally high for both patients and doctors. Improving the accuracy and specificity of nomograms will require incorporating additional biomarkers and longer-term validation studies.